Head to Head Comparison: Quidel Corporation (QDEL) and Its Competitors
Quidel Corporation (NASDAQ: QDEL) is one of 82 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its rivals? We will compare Quidel Corporation to similar companies based on the strength of its analyst recommendations, profitability, risk, earnings, valuation, dividends and institutional ownership.
Insider and Institutional Ownership
87.2% of Quidel Corporation shares are owned by institutional investors. Comparatively, 53.1% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 22.0% of Quidel Corporation shares are owned by insiders. Comparatively, 16.8% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Quidel Corporation has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Quidel Corporation’s rivals have a beta of 0.89, indicating that their average stock price is 11% less volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for Quidel Corporation and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Quidel Corporation Competitors||416||2180||3387||122||2.53|
Quidel Corporation presently has a consensus target price of $31.75, indicating a potential downside of 11.34%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 20.89%. Given Quidel Corporation’s stronger consensus rating and higher possible upside, analysts clearly believe Quidel Corporation is more favorable than its rivals.
This table compares Quidel Corporation and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Quidel Corporation Competitors||-330.26%||-33.54%||-12.51%|
Valuation & Earnings
This table compares Quidel Corporation and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Quidel Corporation||$214.11 million||$39.38 million||-3,577.42|
|Quidel Corporation Competitors||$2.02 billion||$430.37 million||-56.73|
Quidel Corporation’s rivals have higher revenue and earnings than Quidel Corporation. Quidel Corporation is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Quidel Corporation beats its rivals on 9 of the 12 factors compared.
About Quidel Corporation
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.
Receive News & Stock Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related stocks with our FREE daily email newsletter.